7 September 2012. Health technology assessment (HTA) and its increased influence on healthcare payers’ decisionmaking process has a potentially profound impact on medtech manufacturers. In this article, Dr Mark Charny examines the different components of HTA in Europe and whether a pan-EU HTA system is viable, as well as the growing importance of evidence-based medicine to help define the most effective clinical care.

Download This Publication